Washington Food and Drug Administration advisers recommended Wednesday that drugs like Ritalin used to treat attention deficit hyperactivity disorder don't have to carry strong "black box" warnings about possible cardiovascular and psychiatric risks.
An FDA advisory committee's decision breaks ranks with another committee, which voted last month to include the warnings on the drug labels. Wednesday's decision recommends that drug labels be written more clearly so people can understand them.
Some experts said adding the warnings to the drugs - which include Adderall and Strattera - could do more harm than good.
Nearly 3.3 million Americans age 19 and younger used an ADHD drug last year, according to Medco Health Solutions Inc., a prescription drug benefit program manager.